Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Sierra J; Chevallier P; Gohring G; Passweg J; Peniket A; van Biezen A; Koenecke C; Milpied N; Scheid C; de Wreede L; Cahn JY; Petersen E; Volin L; Espiga CR; Cornelissen JJ; Finke J; Kroger N; de Witte T; Maertens J; Ljungman P; Beelen D; Russell N; Crawley C; Mufti G; Alessandrino EP; Veelken JH; Robin M; Itala-Remes M
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Sierra J
Chevallier P
Gohring G
Passweg J
Peniket A
van Biezen A
Koenecke C
Milpied N
Scheid C
de Wreede L
Cahn JY
Petersen E
Volin L
Espiga CR
Cornelissen JJ
Finke J
Kroger N
de Witte T
Maertens J
Ljungman P
Beelen D
Russell N
Crawley C
Mufti G
Alessandrino EP
Veelken JH
Robin M
Itala-Remes M
NATURE PUBLISHING GROUP
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042717373
https://urn.fi/URN:NBN:fi-fe2021042717373
Tiivistelmä
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P < 0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P < 0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.
Kokoelmat
- Rinnakkaistallenteet [19207]